{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_008",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:f0a872ac90651fa1086c74f3324af7797fd987a2db2d115a740badc75708d632",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:14.614590",
  "content": "## 2024-04-22 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 105\n- Screen Failures Cumulative: 12\n- Withdrawals Cumulative: 2\n\n### Enrollment by Dose Group\n- Low Dose: 25\n- Mid Dose: 27\n- High Dose: 26\n- Placebo: 29\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 45.6\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 17.8\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 74.3\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 121.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 82.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 16.1\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 83.3\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 33.0\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 120.8\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 191.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 130.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 36.0\n\n#### High Dose\n- IgG Titer (GMU) Mean: 106.0\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 40.8\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 176.1\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 257.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 180.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 45.0\n\n#### Placebo\n- IgG Titer (GMU) Mean: 5.9\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 3.4\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 10.9\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 21.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 17.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 7.7\n\n### Injection Site Reactions\n- Pain Percentage: 47.4\n- Erythema Percentage: 19.4\n- Swelling Percentage: 14.5\n- Induration Percentage: 8.8\n- Mean Pain Duration (Hours): 17.7\n\n### Systemic Reactogenicity\n- Fever Percentage: 15.2\n- Fatigue Percentage: 31.9\n- Myalgia Percentage: 19.0\n- Headache Percentage: 26.4\n- Chills Percentage: 5.3\n\n### Safety Labs\n- WBC (K) Mean: 7.2\n- WBC (K) SD: 1.8\n- Lymphocyte Percentage Mean: 26.0\n- Lymphocyte Percentage SD: 5.8\n- Neutrophil Percentage Mean: 52.9\n- Neutrophil Percentage SD: 6.9\n- Platelets (K) Mean: 219\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 2.0\n- CRP (mg/L) SD: 1.2\n- Hemoglobin (g/dL) Mean: 14.6\n- Hemoglobin (g/dL) SD: 1.4\n\n### Adverse Events\n- AE ID: VI-AE-0818, Description: lymphadenopathy, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-0817, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- Reactogenicity diary card collection rate: 95%\n- Vaccine lot VX-645 temperature excursion assessed: within acceptable range\n\n### Notes\n- Week 8: Immunogenicity assessments on schedule. 107 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 8,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}